Navigation Links
EDURANT™ 96-Week Phase 3 Safety and Efficacy Data Presented at International AIDS Society Conference
Date:7/19/2011

TITUSVILLE, N.J., July 19, 2011 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor (NNRTI) EDURANT™ (rilpivirine) tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults. The pooled analysis at 96 weeks showed that 78 percent of patients achieved and sustained an undetectable plasma viral load (HIV-1 RNA less than 50 copies/mL) while taking EDURANT as part of combination therapy. These findings were presented today at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome, Italy.

Pooled ECHO and THRIVE results for EDURANT and EFV, each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults, showed that 78 percent of patients in both the EDURANT arm (n=686) and the EFV arm (n=682) reached an undetectable viral load at 96 weeks.  These data demonstrated non-inferiority (12 percent margin) of EDURANT to EFV in lowering viral load in this population at 96 weeks, consistent with the 48-week primary analysis.  Patients taking EDURANT had a virologic failure rate of 14 percent compared to 8 percent experienced by patients taking EFV, of which 3 percent and 2 percent occurred in the second year of treatment, respectively.  Upon virologic failure, the emergence of resistance and cross-resistance to the NNRTI class was higher in the EDURANT arm compared to the EFV arm.

"Finding safe and tolerable regimens over an extended period of time is so important in HIV care, and it is encouraging to see that the 96-week data for EDURANT remain fairly consistent with what we have seen previously," said Calvin J. Cohen, M.D., M.Sc., lead clinical investigator of EDURANT Phase 3 trials and Rese
'/>"/>

SOURCE Janssen Therapeutics, Division of Janssen Products, LP
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... LA JOLLA, Calif. , May 21, 2013 /PRNewswire/ ... a biopharmaceutical company leading the discovery and development of ... Garry E. Menzel , Ph.D., Chief Operating Officer ... overview at the Deutsche Bank 38th Annual Healthcare Conference ... The conference is being held at the Westin Boston ...
(Date:5/21/2013)... (NASDAQ: LCAV ), a leading provider of laser ... that all nominees to the company,s Board of Directors were ... These Directors are: , William F. Bahl ... Counsel , John C. Hassan , ... Heizer III , Chairman of Manus Health Systems, Inc. ...
(Date:5/21/2013)... 21, 2013  Zacks.com announces the list of stocks ... Equity Research analysts discuss the latest news and events ... in the blog include Actavis, Inc.,s (NYSE: ACT ... (NYSE: TOT ), Petrobras (NYSE: PBR ) ... (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO ) Get ...
Breaking Medicine Technology:Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 2The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 3The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 4The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 5
... 2011 OrbusNeich today announced that 12-month follow-up data from ... ccelerated L ining I nhibits N eointimal ... EuroIntervention demonstrated good clinical outcomes with ... the company,s Genous Stent. Target vessel failure (TVF), ...
... school hockey coach is taking the pro-active approach to ... coaches at Stevenson High School, invented the Shockwave ... risk of sustaining a concussion, including athletes, firefighters and ... is a three-step system, starting with baseline testing to ...
Cached Medicine Technology:Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genous™ Stent 2Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genous™ Stent 3Shockwave System Developed to Aid Concussion Detection 2
(Date:5/21/2013)... Bradley, Illinois (PRWEB) May 21, 2013 ... living community], a BMA affordable assisted living community, is hosting ... Don'ts of Arthritis at 2 p.m. on Tuesday, May 28. ... in Dwight, Illinois, serves older adults of all incomes, including ... independence. , The Arthritis program is open to the public. ...
(Date:5/21/2013)... (May 22, 2013)Today the George Washington (GW) ... Services (SPHHS) announced the launch of the ... Health, a collaboration between SPHHS, the Maryland ... other community partners. This university-community partnership aims ... affect Latino communities through research, mutual capacity ...
(Date:5/21/2013)... 21, 2013 Patients of Dr. Michael Shenk ... lost teeth due to gum disease and would like permanent ... disease treatment with laser gum surgery. Gum disease ... highest success rate out of all tooth replacement options. ... relatively new procedure cleared by the Food and Drug Administration ...
(Date:5/21/2013)... on a large scale is the cornerstone of ... better outcomes, better value and better experience of ... patient-centered medical home model offers a viable solution ... of Health and Human Services, Agency for Healthcare ... more about the processes and determinants of successful ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3
... Colorado that involves door-to-door counseling in low-income Hispanic ... and "is raising questions about whether different strategies ... the Denver Rocky Mountain News reports. ... increase, which so far directed $61 million to ...
... time, physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in ... of an antibody to directly target the blood supply ... unharmed. ,The Phase I clinical trial tested ... membrane antigen (PSMA). ,PSMA has been an ...
... participation in a national study, patients being treated ... at North Shore University Hospital// (NSUH) and Long ... that an arsenic compound, coupled with standard chemotherapy ... all had newly-diagnosed acute promyelocytic leukemia, or APL, ...
... first time have used stem cells from the hair follicles ... is much more efficient than the other existing procedures and ... ,This study was undertaken by a team from Laboratory of ... York City and was published in the current issue of ...
... standard breast cancer therapy drug tamoxifen, to another one exemestane//, ... Publishing their findings in the online version of The Lancet, ... UK, and team, stood for changing treatments tracks to exemestane ... it reduced deaths by 17 percent. ,Their findings ...
... who develop lung cancer as 10 to 15 percent//. ... offer support to these estimates, in the form of similar ... of Oncology, Dr. Heather Wakelee of Stanford University in California ... lung cancer patients are women who have never smoked. ...
Cached Medicine News:Health News:First Treatment to Directly Target Tumor Blood Supply 2Health News:First Treatment to Directly Target Tumor Blood Supply 3Health News:Arsenic Compound Effective in Treating Rare Leukemia 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: